A DNA Aptamer That Inhibits the Aberrant Signaling of Fibroblast Growth Factor Receptor in Cancer Cells.
Journal
JACS Au
ISSN: 2691-3704
Titre abrégé: JACS Au
Pays: United States
ID NLM: 101775714
Informations de publication
Date de publication:
24 May 2021
24 May 2021
Historique:
received:
22
12
2020
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
2
9
2021
Statut:
epublish
Résumé
Growth factor receptors are activated through dimerization by the binding of their ligands and play pivotal roles in normal cell function. However, the aberrant activity of the receptors has been associated with cancer malignancy. One of the main causes of the aberrant receptor activation is the overexpression of receptors and the resultant formation of unliganded receptor dimers, which can be activated in the absence of external ligand molecules. Thus, the unliganded receptor dimer is a promising target to inhibit aberrant signaling in cancer. Here, we report an aptamer that specifically binds to fibroblast growth factor receptor 2b and inhibits the aberrant receptor activation and signaling. Our investigation suggests that this aptamer inhibits the formation of the receptor dimer occurring in the absence of external ligand molecules. This work presents a new inhibitory function of aptamers and the possibility of oligonucleotide-based therapeutics for cancer.
Identifiants
pubmed: 34467321
doi: 10.1021/jacsau.0c00121
pmc: PMC8395645
doi:
Types de publication
Journal Article
Langues
eng
Pagination
578-585Informations de copyright
© 2021 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Cancer Res. 2008 Apr 1;68(7):2340-8
pubmed: 18381441
Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66
pubmed: 25772309
Mol Ther Methods Clin Dev. 2016 Apr 06;5:16014
pubmed: 27088106
Cancer Cell. 2009 May 5;15(5):429-40
pubmed: 19411071
Curr Biol. 2001 Apr 17;11(8):R292-5
pubmed: 11369216
Chem Commun (Camb). 2019 Feb 26;55(18):2672-2675
pubmed: 30746545
Chem Commun (Camb). 2014 Nov 7;50(86):13131-4
pubmed: 25223895
Nat Commun. 2016 Jan 04;7:10262
pubmed: 26725515
Mod Pathol. 2016 Sep;29(9):1095-103
pubmed: 27230412
Crit Rev Oncol Hematol. 2020 Nov;155:103091
pubmed: 32961472
Nucleic Acid Ther. 2015 Oct;25(5):227-34
pubmed: 26125598
J Am Chem Soc. 2019 Aug 14;141(32):12673-12681
pubmed: 31381313
Chirality. 2008 Mar;20(3-4):431-40
pubmed: 17853398
Molecules. 2010 Jan 07;15(1):215-25
pubmed: 20110884
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2266-71
pubmed: 12591959
J Biol Chem. 1998 May 22;273(21):13230-5
pubmed: 9582367
J Biol Chem. 1994 Dec 23;269(51):32023-6
pubmed: 7798193
PLoS One. 2011;6(6):e20299
pubmed: 21687663
Int J Mol Med. 2009 Mar;23(3):307-11
pubmed: 19212647
Antisense Nucleic Acid Drug Dev. 2002 Oct;12(5):289-99
pubmed: 12477279
Mol Ther Nucleic Acids. 2020 Mar 6;19:1145-1152
pubmed: 32059340
Breast. 2018 Feb;37:126-133
pubmed: 29156384
Nucleic Acids Res. 2016 Feb 29;44(4):1909-23
pubmed: 26740584
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3745-9
pubmed: 8475124
Oncotarget. 2015 Feb 10;6(4):2009-22
pubmed: 25576915
Pharmaceuticals (Basel). 2013 Aug 29;6(9):1082-93
pubmed: 24276420
Cancer Cell. 2004 Apr;5(4):317-28
pubmed: 15093539
Mol Cell. 2006 Mar 3;21(5):711-7
pubmed: 16507368
Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262
pubmed: 29246304
Oncogene. 2013 Jun 20;32(25):3059-70
pubmed: 22869148
Cells. 2019 May 29;8(6):
pubmed: 31146385
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):579-82
pubmed: 26592704
Mol Ther Nucleic Acids. 2019 Sep 6;17:530-539
pubmed: 31357131
J Biol Chem. 1999 Mar 26;274(13):8865-74
pubmed: 10085130
Cancer Res. 2004 Nov 1;64(21):7962-70
pubmed: 15520203
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W676-82
pubmed: 16845096
Cancer Res. 2010 Mar 1;70(5):2085-94
pubmed: 20179196
Nat Rev Drug Discov. 2017 Mar;16(3):181-202
pubmed: 27807347
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9226-31
pubmed: 12874383
Oncotarget. 2017 Feb 28;8(9):16052-16074
pubmed: 28030802
Sci Adv. 2020 Apr 01;6(14):eaay2801
pubmed: 32270033
Cancer Res. 2012 Apr 15;72(8):2045-56
pubmed: 22369928
Mol Cancer Ther. 2015 Nov;14(11):2613-22
pubmed: 26351320
Patholog Res Int. 2012;2012:574768
pubmed: 22701813
Front Genet. 2019 Feb 12;10:102
pubmed: 30809251
Annu Rev Biochem. 1988;57:443-78
pubmed: 3052279